[Immunology in clinical practice. XII. Indications for T-Cell-mediated immunotherapy of cancer].
In a limited number of cases, T cell based cancer immunotherapy has proven its clinical efficacy. Indications are restricted to certain haematological malignancies, relapsed after allogeneic bone marrow transplantation, and tumours against which an autologous T cell response can be elicited or boosted, such as melanomas and renal carcinomas. T cell based immunotherapy of non-immunogenic tumors is possible using bispecific antibodies.
Beun
G D
GD
Eli Lilly Nederland, Medische Afdeling, Leiden.
D018033:Antibodies, Bispecific / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000276:immunology; D002292:Carcinoma, Renal Cell / Q000628:therapy; D006086:Graft vs Host Disease / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007680:Kidney Neoplasms / Q000628:therapy; D007938:Leukemia / Q000276:immunology; D008545:Melanoma / Q000628:therapy; D009369:Neoplasms / Q000628:therapy*; D012008:Recurrence; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D018033:Antibodies, Bispecific